Gyre Therapeutics (GYRE) Gains from Sales and Divestitures (2012 - 2013)
Gyre Therapeutics (GYRE) reported Gains from Sales and Divestitures of $803484.0 for Q4 2013, down 9.87% year-over-year from $891443.0 in Q4 2012, and down 9.87% quarter-over-quarter from $891443.0 in Q4 2012.
Gyre Therapeutics (GYRE) Gains from Sales and Divestitures (2012 - 2013) Analysis & Trends
Gyre Therapeutics (GYRE) has 2 years of Gains from Sales and Divestitures data on file, last reported at $803484.0 in Q4 2013.
- Gains from Sales and Divestitures for Q4 2013 came in at $803484.0, down 9.87% year-over-year; the trailing twelve-month figure through Dec 2013 was $803484.0 (down 9.87% YoY), and the FY2013 annual result was $803484.0, down 9.87% from the prior year.
- Gains from Sales and Divestitures slipped to $803484.0 in Q4 2013 per GYRE's latest filing, from $891443.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $891443.0 in Q4 2012 and troughed at $803484.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 803,484.00 |
| Dec 31, 2013 | 803,484.00 |
| Dec 31, 2012 | 891,443.00 |
| Dec 31, 2012 | 891,443.00 |